NEW YORK, June 18, 2018 /PRNewswire/ — WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of China Biologic Products Holdings, Inc. (“CBPO” or the “Company”) (NASDAQ: CBPO) in connection with the proposed acquisition of the Company by Chinese investment firm CITIC Capital Holdings Ltd. Under the terms of the acquisition agreement, CBPO shareholders will receive $110 in cash for each share they own.
WeissLaw is investigating whether CBPO’s Board acted to maximize shareholder value prior to entering into the agreement. Notably, the per-share offer price is nearly $5.00 less than the Company’s 52-week high of $114.82, and $22.00 less than the analyst target price of $132.00 per share.
Given these facts, WeissLaw is investigating whether CBPO’s Board acted in the best interests of CBPO’s public shareholders to maximize shareholder value prior to entering into the agreement. If you own CBPO shares and would like more information about your rights or our investigation, or if you have information to share with us, please contact Joshua Rubin by telephone at (888) 593-4771 or by email at email@example.com.
WeissLaw LLP has litigated hundreds of stockholder class and derivative actions for violations of corporate and fiduciary duties. We have recovered over a billion dollars for defrauded clients and obtained important corporate governance relief in many of these cases. If you have information or would like legal advice concerning possible corporate wrongdoing (including insider trading, waste of corporate assets, accounting fraud, or materially misleading information), consumer fraud (including false advertising, defective products, or other deceptive business practices), or anti-trust violations, please email us at firstname.lastname@example.org or fill out the form on our website, http://www.weisslawllp.com/china-biologic-products-holdings-inc/
SOURCE WeissLaw LLP